Cogstate Ltd (ASX: CGS) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

CogState Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $307.78 million
P/E Ratio 384.62
Dividend Yield N/A
Shares Outstanding 170.99 million
Earnings per share 0.003
Dividend per share N/A
Year To Date Return 43.64%
Earnings Yield 0.26%
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of May 24th 2021

Cogstate Ltd (ASX: CGS)
Latest News

CGS ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Cogstate Ltd

Cogstate Ltd is a cognitive science company. The principal activity of the company is a sale of technology and services for the measurement of cognition, where services include scientific consultancy, project management, data management, statistical analysis and reporting. Its operating segment includes Clinical Trials; Healthcare and Research. The company generates maximum revenue from the Clinical Trials segment. In clinical trials segment, technology and services are soldto pharmaceutical, biotechnology, nutraceutical, and functional food companies.

CGS Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
27 Jul 2021 $1.80 $0.05 2.86% 181,668 $1.76 $1.92 $1.76
26 Jul 2021 $1.75 $0.17 10.76% 1,336,204 $1.61 $1.80 $1.60
23 Jul 2021 $1.58 $0.12 8.22% 1,172,722 $1.47 $1.66 $1.46
22 Jul 2021 $1.46 $0.02 1.39% 204,927 $1.46 $1.52 $1.45
21 Jul 2021 $1.44 $0.01 0.70% 5,333 $1.44 $1.44 $1.43
20 Jul 2021 $1.43 $0.07 5.13% 79,547 $1.41 $1.44 $1.37
19 Jul 2021 $1.37 $-0.06 -4.21% 12,889 $1.43 $1.43 $1.37
16 Jul 2021 $1.43 $0.05 3.62% 35,237 $1.38 $1.46 $1.38
15 Jul 2021 $1.38 $-0.04 -2.82% 137,066 $1.48 $1.49 $1.37
14 Jul 2021 $1.42 $0.00 0.00% 121,280 $1.45 $1.47 $1.42
13 Jul 2021 $1.42 $-0.01 -0.70% 68,179 $1.45 $1.49 $1.42
12 Jul 2021 $1.43 $0.03 2.14% 136,125 $1.40 $1.45 $1.38
09 Jul 2021 $1.40 $0.03 2.20% 46,823 $1.37 $1.40 $1.36
08 Jul 2021 $1.37 $-0.03 -2.14% 140,075 $1.43 $1.46 $1.37
07 Jul 2021 $1.40 $0.00 0.00% 153,129 $1.42 $1.44 $1.39
06 Jul 2021 $1.40 $0.04 2.94% 90,700 $1.37 $1.41 $1.37
05 Jul 2021 $1.36 $-0.09 -6.21% 114,216 $1.43 $1.48 $1.36
02 Jul 2021 $1.45 $0.06 4.32% 389,563 $1.42 $1.51 $1.42
01 Jul 2021 $1.39 $0.03 2.21% 34,991 $1.39 $1.39 $1.39
30 Jun 2021 $1.36 $-0.01 -0.73% 49,751 $1.39 $1.39 $1.35
29 Jun 2021 $1.37 $-0.01 -0.72% 60,008 $1.40 $1.43 $1.37

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
23 Mar 2021 Bradley O'Connor Exercise 750 $630,000
Exercise of options.
23 Mar 2021 Bradley O'Connor Buy 750 $630,000
Exercise of options.
09 Mar 2021 Bradley O'Connor Sell 2 $2,025,000
On-market trade.
02 Nov 2020 Bradley O'Connor Issued 1 $1,387,500
Issue of options.
22 Oct 2020 Richard van den Broek Exercise 50 $13,000
Exercise of options.
22 Oct 2020 Richard van den Broek Issued 50 $13,000
Exercise of options.
22 Oct 2020 David Dolby Exercise 100 $26,000
Exercise of options.
22 Oct 2020 David Dolby Issued 100 $26,000
Exercise of options.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Martyn Kenneth Myer Non-Executive ChairmanNon-Executive Director Oct 1999
Mr Myer is President of The Myer Foundation, one of two principle Myer Family philanthropic funds, and on the Fishermans Bend board. He previously served as Deputy Chancellor of the Council of the University of Melbourne, President of the Howard Florey Institute of Experimental Physiology and Medicine and was a director of The Florey Institute of Neuroscience and Mental Health, where he had participate in the transition of the Institute's research focus towards diagnostic and therapeutic neuroscience, including a focus on degenerative brain diseases. He is a member of the Risk and Compliance Committee. He is a Director of Cogstate Inc., Cogstate Health Inc., Cogstate Canada Inc., Cogstate Sports Pty Ltd and Cogstate Spain SL.
Mr Bradley O'Connor Chief Executive OfficerManaging Director Nov 2005
Mr O'Connor held senior positions at Spherion Group, Australian Wine Exchange and PricewaterhouseCoopers. He is a Director of Cogstate Inc., Cogstate Health Inc., Cogstate Canada Inc., Cogstate Sports Pty Ltd, Cogstate Healthcare LLC and Cogstate Spain SL.
Ms Ingrid Anne Player Non-Executive Director Aug 2019
Ms Player brings healthcare sector experience and commercial expertise to the Board. She has held senior executive roles with Healthscope Ltd, a private healthcare provider in Australia, including the former positions of Group Executive - Legal, Governance and Sustainability, and General Counsel and Company Secretary from 2005 until 2019. Ms Player also has international commercial and regulatory experience that spans a range of markets and industries, which she gained in private legal practice in Australia and in The Netherlands. She is a Chair of the Risk and Compliance Committee.
Mr Richard van den Broek Non-Executive Director Aug 2010
Mr van den Broek is founder and managing partner of HSMR Advisors LLC. Prior to his time as an investor in the healthcare industry he had a ten year career as a biotech analyst, starting at Oppenheimer & Co., then Merrill Lynch, and finally at Hambrecht & Quist.
Mr David Dolby Non-Executive Director Nov 2013
Mr Dolby is founder and CEO of Dolby Family Ventures. He represents the Dolby Family Trust on a number of technology, scientific research, and consumer products investments focusing on innovation and commercialising intellectual property. He is a Director of Dolby Laboratories (from 2011), Salk Institute for Biological Sciences (from 2019), Academy Museum of Motion Pictures (from 2019), Tipping Point Community (from 2015), CFO of the Ray and Dagmar Dolby Family Fund (since 2010).
Dr Richard Mohs Non-Executive Director Jan 2017
Dr Mohs is currently Chief Scientific Officer for the Global Alzheimer's Platform (GAP) Foundation. He also serves as a consultant to academic institutions, foundations and biopharmaceutical companies, and is a Member of the Board of Governors for the Alzheimer's Drug Discovery Foundation. Dr Mohs retired from Eli Lilly in 2015, where he held leadership positions including Vice President for Neuroscience Early Clinical Development and Leader of the Global Alzheimer's Drug Development Team. Before Eli Lilly, Dr Mohs has had spend 23 years with the Mount Sinai School of Medicine where he was Professor in the Department of Psychiatry and Associate Chief of Staff for Research at the Bronx Veterans Affairs Medical Centre. Dr Mohs is a member of the Risk and Compliance Committee.
Ms Kim Wenn Non-Executive Director Nov 2020
Ms Wenn has technology experience and commercial knowledge, with over 30 years experience in innovation roles. Until July 2018, Kim held the role of Chief Information Officer at Tabcorp Holdings, an ASX50 listed company. Kim's experience includes, among other things, business strategy, governance and change management-with a focus on digital disruption. In addition to her role at Cogstate, Kim is a Non-Executive Director at Volt Bank.
Mr David Franks Company Secretary Feb 2021
-
Ken Billard Chief Commercial Officer
-
Paul Maruff Chief Science Officer
-
David Franks Company Secretary
-
John Glueck General Counsel
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
National Nominees Limited 29,485,793 17.40%
Dagmar Dolby 21,754,028 12.80%
Citicorp Nominees Pty Limited 16,494,261 9.70%
Myer & Myer Pty Ltd 14,424,569 8.50%
HSBC Custody Nominees (Australia) Limited 13,771,347 8.10%
Nebula Neuro Pty Ltd 8,800,000 5.20%
Anacacia Pty Limited 7,093,445 4.20%
Mpyer Investments Pty Ltd 6,061,872 3.60%
Mr Bradley John O'Connor 4,955,929 2.90%
BNP Paribas Nominees Pty Ltd 3,223,232 1.90%
Myer & Myer Pty Ltd i 2,563,000 1.50%
Dr Peter Anthony Bick & Ms Melanie Jo Gribble 2,500,000 1.50%
David Dolby Investments II LLC 2,202,274 1.30%
HSBC Custody Nominees (Australia) Limited GSCO ECA 1,828,357 1.10%
Dagmar Dolby i 1,776,500 1.00%
Mutual Trust Pty Ltd 1,343,806 0.80%
Mr Alistair David Strong 1,320,000 0.80%
Mr David Alexander Simpson & Mrs Dawn Gentry Simpson 1,263,689 0.70%
Beta Gamma Pty Ltd 1,220,000 0.70%
Howitt Nominees Pty Ltd 1,100,000 0.60%

Profile

since

Note